Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-RA-P01 immunogenicity biomarker study in rheumatoid arthritis
NL-OMON41266Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of adalimumab, etanercept, infliximab, rituximab and tocilizumab in rheumatoid arthritis (RA) (6 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Anti-drug antibodies against biologic therapy at 1 year and Early biomarkers within 3 months predicting immunization within 1 year. Started Jun 2014; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41266.